SecBot SecBot
PRESS-RELEASE ·Filed Mar 17, 2026

INKT

MiNK Therapeutics
NEUTRAL
Impact 4/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor the March 31 earnings call for financial clarity and any updates on cash runway, R&D spend, or clinical trial progress. The C-Further/Southampton collaboration adds strategic value but does not materially alter near-term financials.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.57
T+0 close · Mar 17, 2026 · via day close
Latest settled
+23.51%
T+60 · $11.82
Vs SPY
+13.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 17 $9.57entry
  2. T+1 · 8mo ago −1.15%α +0.25% · $9.46
  3. T+5 · 8mo ago −10.55%α −7.90% · $8.56
  4. T+20 · 7mo ago +35.21%α +30.91% · $12.94
  5. T+60 · 5mo ago +23.51%α +13.65% · $11.82
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics announced it will report Q4 and full-year 2025 financial results on March 31, 2026, alongside a corporate update on clinical progress and its iNKT cell therapy platform. The press release highlights a new collaboration with C-Further and the University of Southampton to develop a PRAME-targeted iNKT therapy for pediatric cancers, bringing non-dilutive funding and strategic validation. However, no actual financial data was disclosed in this announcement.

Key Facts

  • MiNK Therapeutics will report Q4 and full-year 2025 financial results on March 31, 2026, before market open.
  • Company to host a conference call at 8:30 a.m. ET to discuss results and provide a corporate update.
  • New collaboration with C-Further and University of Southampton on a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers.
  • Collaboration includes non-dilutive funding and potential downstream commercial revenue.
  • No financial results (revenue, EPS, cash position) were released in this announcement.

Financial Impact

No financial data disclosed, impact deferred to earnings release

Risk Factors

  • No financial metrics provided, actual results could miss expectations.
  • High cash burn typical for clinical-stage biotechs; funding needs could emerge if partnerships don't scale.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257040

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026